DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: Eli Lilly Nederland B.V.
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Portrazza is a monoclonal antibody used with gemcitabine and cisplatin to treat metastatic squamous non-small cell lung cancer, indicating for use only for patients with squamous non-small cell lung cancer. It targets the EGFR protein and prevents cancer cells’ growth and promotes cell death.